Quick Answer
Polaryx Therapeutics, Inc. reported Diluted EPS of $0.20 per share (loss) for fiscal year 2025.
Polaryx Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.20 | +77.5% |
| 2024 | -$0.89 | — |
- Polaryx Therapeutics, Inc. showed an increase of +77.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, Polaryx Therapeutics, Inc.’s diluted eps has grown by 77.5% (from $0.89 per share (loss) to $0.20 per share (loss)).
- The most recent figure is from Polaryx Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: